Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Nomura Elevates SINO BIOPHARM's TP to HKD9.17; Interim Results Largely In Line
Recommend 28 Positive 60 Negative 23 |
||||
|
||||
|
SINO BIOPHARM (01177.HK)'s 1H25 results largely met expectations, according to a report released by Nomura. The company's revenue increased by 10.7% YoY to RMB17.6 billion, basically in line with the broker's and the market's forecasts. Its net profit grew by 12.3% to RMB3.4 billion, beating the broker's forecast by RMB1.9 billion. After excluding income from discontinued operations, SINO BIOPHARM's interim net profit would have nearly doubled to around RMB3.1 billion. Believing that the commercialization and clinical progress of innovative drugs such as TQB3616, TQB2102, and TQC3721 could serve as short-term catalysts for its stock price, Nomura kept a Buy rating on SINO BIOPHARM and lifted its target price from HKD7.69 to HKD9.17. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
